Status:

COMPLETED

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Lead Sponsor:

Morphotek

Conditions:

Adenocarcinoma of the Lung

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin o...

Eligibility Criteria

Inclusion

  • Histologically or cytologically confirmed adenocarcinoma of the lung classified as stage IV
  • Confirmed folate receptor-alpha (FRA) expression by immunohistochemistry (IHC)
  • Measurable disease with at least one unidimensionally measurable lesion according to RECIST criteria version 1.1 by computed tomography (CT) or magnetic resonance imaging (MRI) scans (CT or MRI scans must have been performed within 30 days prior to the first dose of farletuzumab or placebo)
  • Must have received no prior chemotherapy, radiation therapy or surgery with curative intent for adenocarcinoma of the lung

Exclusion

  • Participants who have had previous chemotherapy for adenocarcinoma of the lung
  • Prior surgery with curative intent for adenocarcinoma of the lung
  • Prior radiotherapy for adenocarcinoma of the lung. (Prior treatment with local radiotherapy for symptom control \[i.e., palliative radiation with non-curative intent\] is permitted)

Key Trial Info

Start Date :

June 27 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2013

Estimated Enrollment :

130 Patients enrolled

Trial Details

Trial ID

NCT01218516

Start Date

June 27 2011

End Date

November 1 2013

Last Update

August 20 2020

Active Locations (93)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 24 (93 locations)

1

Ironwood Cancer and Research Center

Chandler, Arizona, United States, 85224

2

Arizona Center for Hematology Oncology

Glendale, Arizona, United States, 85306-4666

3

Providence Health System

Beverly Hills, California, United States, 90210-5501

4

Cancer Care Associates of Fresno Medical Group, Inc.

Fresno, California, United States, 93720

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | DecenTrialz